All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub was pleased to speak to Gabriela Hobbs, Massachusetts General Hospital, Boston, US. We asked: How would you manage a young man with polycythemia vera (PV) and fatigue?
How would you manage a young man with polycythemia vera and fatigue?
Although risk-stratification scores for cytoreduction therapy for PV only take into account thrombosis, knowledge of additional systemic symptoms are key for the management of patients with PV. Fatigue is the most common symptom of PV, and Gabriela Hobbs emphasizes the importance of good sleep hygiene, managing comorbidities, and adopting a healthy lifestyle to optimize energy.
For a young patient with PV, cytoreduction is usually the last port of call, however, there are some instances, as outlined in this interview, when individuals may be eligible.
Subscribe to get the best content related to MPN delivered to your inbox